Alkermes plc

ALKS Q3 2025

Reported: 2025-10-28

Alkermes reported robust third-quarter results, driven by strong product performance and strategic advancements, prompting an increase in 2025 financial guidance.

Key takeaways

Total revenues reached $394.2 million, with proprietary product sales increasing 16% year-over-year to $317.4 million.
The proposed acquisition of Avadel Pharmaceuticals is expected to enhance Alkermes' position in the sleep medicine market and diversify its product portfolio.
GAAP net income for the quarter was $82.8 million, demonstrating strong profitability alongside a significant gross-to-net benefit from Medicaid utilization.
Research and development expenses rose to $81.7 million, reflecting investment in ongoing and upcoming clinical studies for orexin receptor agonists.
Full-year 2025 guidance increased, underlining confidence in sustained commercial traction and operational execution.

View recap

Amkor Technology, Inc.

AMKR Q3 2025

Reported: 2025-10-28

Amkor Technology delivered a robust Q3 2025 with revenue of $1.99 billion and EPS of $0.51, both exceeding guidance and driven by strong demand in advanced packaging across communications and computing markets.

Key takeaways

Revenue rose 31% sequentially, reflecting record performance in communications and computing sectors.
Communications revenue surged 67% sequentially, bolstered by iOS product launches and a 17% year-on-year growth in Android.
Gross margin expanded to 14.3%, up 230 basis points quarter-over-quarter, benefiting from higher production volumes.
Strategic investments continue, highlighted by a $7 billion advanced packaging campus in Arizona, aimed at enhancing supply chain resilience and expanding domestic manufacturing capabilities.
Full-year outlook remains optimistic with year-on-year growth expected in advanced and mainstream portfolios despite anticipations of some sequential decline in Q4.

View recap

American Tower Corporation (REIT)

AMT Q3 2025

Reported: 2025-10-28

American Tower reported a strong third quarter with double-digit growth in attributable AFFO per share, driven by robust leasing activity in both tower and data center segments. The company raised its guidance for the year, highlighting the solid fundamentals of its core operating model.

Key takeaways

Attributable AFFO per share growth projected at approximately 7%, with a 9% growth outlook net of foreign exchange and financing costs.
Record levels of leasing activity, particularly in 5G upgrades, driving increased demand for tower capacity amidst rising mobile data consumption.
Significant momentum in CoreSite with record retail leasing revenue and strong demand for facilities supporting AI-related workloads and hybrid cloud deployments.
Continued emphasis on operational excellence, with 300 basis points of adjusted EBITDA margin expansion since 2020 and further improvements expected.

View recap

A. O. Smith Corporation

AOS Q3 2025

Reported: 2025-10-28

A.O. Smith reported solid Q3 2025 results with a 4% revenue growth, driven primarily by strong North American sales, despite challenges in the Chinese market impacting overall performance.

Key takeaways

Q3 total sales reached $943 million, reflecting a 15% year-over-year increase in EPS to $0.94.
North America segment earnings rose 11% to $180 million, aided by pricing strategies and higher commercial volumes.
Operating cash flow improved by 21% to $434 million, with free cash flow rising 35% to $381 million.
A 6% quarterly dividend increase to $0.36 per share marks the 32nd consecutive annual raise, demonstrating commitment to shareholder returns.
Challenges in the Chinese market led to a 12% sales decline in local currency, though margin expansion was achieved through cost-saving measures.

View recap

Arcutis Biotherapeutics, Inc.

ARQT Q3 2025

Reported: 2025-10-28

Arcutis Biotherapeutics reported robust Q3 2025 results, with net product revenues of $99.2 million, reflecting a substantial 122% year-over-year increase driven by strong demand for its ZORYVE portfolio.

Key takeaways

Net product revenues increased 22% sequentially and 122% compared to Q3 2024, fueled by growing prescription volumes across ZORYVE formulations.
Total prescriptions for ZORYVE rose 13% from Q2 and 92% year-over-year, reaching record weekly averages with over 17,000 scripts.
The recent launch of ZORYVE cream 0.05% for atopic dermatitis (ages 2-5) is expected to further drive sales in the upcoming quarter.
R&D expenses remain stable year-over-year at $19.6 million, with anticipated increases in 2026 for further clinical developments.
Arcutis is nearing cash flow positivity, enabling sustained business investments and growth in the dermatology sector.

View recap

Allegheny Technologies Incorporated

ATI Q3 2025

Reported: 2025-10-28

ATI reported a robust third quarter with revenue exceeding $1.1 billion, a 7% increase year-over-year, and adjusted EPS of $0.85, surpassing projections by $0.10, all driven by strong aerospace and defense demand.

Key takeaways

Aerospace and defense revenue grew by 21% year-over-year, with defense sales up 51%, solidifying ATI's market leadership.
Adjusted EBITDA reached $225 million, exceeding guidance, with margins exceeding 20%, the highest since the pandemic.
Year-to-date cash generated from operations improved significantly to $299 million, coupled with a $150 million return to shareholders through share repurchases.
Full-year adjusted EBITDA guidance raised by $28 million at the midpoint to a range of $848 million to $858 million, underlining strong future growth prospects.

View recap

Bed Bath & Beyond Inc.

BBBY Q3 2025

Reported: 2025-10-28

Bed Bath & Beyond's third quarter results demonstrate sustained progress towards profitability, marked by a significant reduction in net loss and improved gross margins against a challenging retail backdrop.

Key takeaways

Achieved a 93% year-over-year improvement in net loss, totaling $4.5 million.
Adjusted EBITDA loss decreased by 85% to $4.9 million, reflecting enhanced operational efficiency.
Gross margin rose by 420 basis points to 25.3%, driven by reduced fulfillment costs and refined promotional strategies.
Introduced a new private label credit card, aimed at enhancing customer retention and the overall shopping experience.
Raised approximately $113 million through an ATM issuance to strengthen the balance sheet and support strategic investments in technology and PropTech solutions.

View recap

Brown & Brown, Inc.

BRO Q3 2025

Reported: 2025-10-28

Brown & Brown, Inc. reported robust third-quarter results, with revenues growing 35.4% year-over-year and adjusted earnings per share increasing by 15% to $1.05. Strategic leadership appointments and a significant share repurchase program signal continued commitment to long-term growth and value creation.

Key takeaways

Revenues reached $1.6 billion, driven by strong organic growth of 3.5%, despite a challenging economic environment.
Adjusted EBITDAC margin improved by 170 basis points to 36.6%, highlighting operational efficiency.
The board approved a 10% dividend increase and expanded share repurchase authorization to $1.5 billion as part of its commitment to enhance shareholder value.
Seven acquisitions were completed, contributing an estimated $1.7 billion in annual revenues, underscoring the company's proactive growth strategy.
The company remains focused on addressing rising health care costs and maintaining competitive pricing in various insurance segments.

View recap

Avis Budget Group, Inc.

CAR Q3 2025

Reported: 2025-10-28

Avis Budget Group reported a modest year-over-year revenue increase to $3.51 billion, signaling a positive shift in performance and customer engagement strategies.

Key takeaways

Revenue improved by $39 million compared to Q3 2024, marking the first year-over-year increase in eight quarters.
The company emphasizes a strategic focus on enhancing customer experience as a key driver for long-term growth and brand loyalty.
Cost discipline is prioritized alongside investments in product quality and customer service to sustain revenue growth.
The launch of Avis First represents a commitment to delivering consistent and dependable service across its brand portfolio.

View recap

Carrier Global Corporation

CARR Q3 2025

Reported: 2025-10-28

Carrier reported Q3 2025 results in line with expectations, reflecting a $500 million sales challenge due to residential softness, countered by robust growth in Commercial HVAC and cost management initiatives.

Key takeaways

Commercial HVAC sales surged 30%, significantly mitigating challenges in the residential segment.
Aggressive cost-cutting measures, including the elimination of 3,000 indirect positions, aim to enhance operational efficiency.
The company is on track for its fifth consecutive year of double-digit growth in aftermarket services, with 12% growth reported this quarter.
Carrier's Board authorized a new $5 billion share repurchase program, underscoring confidence in future performance.
Strategic investments in heat pump technology and digital platforms are expected to drive long-term growth, particularly in Europe.

View recap

Cadence Design Systems, Inc.

CDNS Q3 2025

Reported: 2025-10-28

Cadence reported strong Q3 2025 results, surpassing expectations with significant revenue growth and a growing backlog, driven by accelerating demand in AI and technology leadership.

Key takeaways

Revenue growth forecast increased to approximately 14% with EPS growth projected at 18% for the year.
Backlog exceeded $7 billion, underscoring strong demand across all product categories.
Expanded partnerships with key industry players, including Samsung, TSMC, and leading semiconductor companies, enhancing market position.
Continued momentum in AI-driven design solutions, with notable success of the Cadence Cerebrus AI Studio delivering substantial productivity improvements.
Strategic acquisition of Arm Artisan Foundation IP enhances design capabilities in advanced node technologies.

View recap

Confluent Inc. Class A Common Stock

CFLT Q3 2025

Reported: 2025-10-28

Confluent reported a strong Q3 2025, exceeding revenue expectations with a notable 19% growth in subscription revenue and continued momentum in its cloud business.

Key takeaways

Subscription revenue reached $286 million, up 19% year-over-year, with Confluent Cloud revenue increasing 24% to $161 million.
Non-GAAP operating margin improved by 3 percentage points to approximately 10%, highlighting effective cost management.
The late-stage pipeline experienced over 40% sequential growth, indicating strong demand for cloud use cases.
More than 1,000 customers utilized Flink in Q3, driving a 70% sequential increase in Flink ARR, showcasing its expanding adoption.
Confluent's partner ecosystem contributed over 25% of new business, further solidifying its market position and customer expansion efforts.

View recap

Georgia Capital PLC

CGEO.L Q3 2025

Reported: 2025-10-28

GCAP reported a robust performance in Q3, highlighted by an 8% increase in NAV per share and nearly 30% EBITDA growth across its portfolio companies, reinforcing strong operational momentum despite external challenges.

Key takeaways

NAV per share rose by 7.9%, driven by strong performance from Bank of Georgia and portfolio companies.
EBITDA growth of nearly 30% was achieved in Q3, maintaining over 30% growth year-to-date.
Share buybacks totaled 1.4 million shares in Q3, with a total of 15.2 million shares repurchased for $221 million, enhancing shareholder value.
Debt levels decreased with a target to be debt-free at the holding company level; $100 million of capital returned as part of an ongoing program.
Revenue grew by 13.5% in Q3, reinforcing the company's high-growth trajectory.

View recap

Check Point Software Technologies Ltd.

CHKP Q3 2025

Reported: 2025-10-28

Check Point's Q3 results demonstrate robust growth with double-digit increases in calculated billings, leading to a 7% rise in revenue to $678 million. The company raises 2025 revenue guidance amid strong demand across its cybersecurity portfolio.

Key takeaways

Calculated billings rose by 20% year-over-year, driven by broad portfolio demand and contributing to overall revenue growth.
Non-GAAP EPS reached $3.94 per diluted share, exceeding guidance, aided by a one-time tax benefit.
The successful acquisition of Lakera enhances Check Point's capabilities in AI security, positioning the company for leadership in safeguarding AI applications.
Services calculated billings experienced strong performance, growing by 21%, reflecting heightened demand across offerings.
The company achieved FedRAMP authorization for its Infinity platform, enhancing its market position within U.S. federal environments.

View recap

Crane Co.

CR Q3 2025

Reported: 2025-10-28

Crane Company delivered strong Q3 2025 results, with adjusted EPS of $1.64 and core sales growth of 5.6%, outperforming expectations and reflecting robust performance across Aerospace & Electronics and Process Flow Technologies.

Key takeaways

Adjusted EPS increased to $1.64, driven by broad-based strength in core sales, particularly in Aerospace & Electronics.
Full-year adjusted EPS outlook raised to $5.75-$5.95, signaling a 20% growth compared to last year.
Pending acquisition of Precision Sensors & Instrumentation remains on track for January 1, with integration planning well underway and expected to enhance financial performance and growth.
Aerospace & Electronics segment anticipates low double-digit core sales growth for the year, supported by strong demand in defense and commercial markets.
Crane's robust M&A pipeline includes opportunities in both Aerospace & Electronics and Process Flow Technologies, with potential deal sizes between $100 million and $500 million.

View recap

D.R. Horton, Inc.

DHI Q4 2025

Reported: 2025-10-28

D.R. Horton reported solid fourth quarter results, with a 5% increase in net sales orders and a consolidated pretax income of $1.2 billion on revenues of $9.7 billion, highlighting strong operational discipline amidst a challenging market.

Key takeaways

Fourth quarter net income reached $905.3 million, translating to $3.04 per diluted share, consistent with ongoing profitability amid market constraints.
Gross profit margin on home sales declined to 20%, reflecting higher incentive costs and increased litigation expenses.
D.R. Horton commenced 14,600 homes in Q4, reducing unsold inventory to 19,600 homes, which positions the company for improved cycle times and efficiency.
The company returned $4.8 billion to shareholders through buybacks and dividends, reaffirming its commitment to capital efficiency and value creation.
Average sales price of homes decreased by 3% year-over-year, emphasizing D.R. Horton's focus on affordable homeownership in a competitive landscape.

View recap

Forestar Group Inc.

FOR Q4 2025

Reported: 2025-10-28

Forestar reported a strong finish to fiscal 2025, achieving $670 million in fourth-quarter revenue and $1.7 billion for the year, signaling resilience amidst a challenging housing market.

Key takeaways

Fourth-quarter net income rose 7% to $87 million, resulting in a full-year net income of $168 million.
Revenue increased 22% in the fourth quarter and 10% for the year, exceeding prior guidance, with significant contributions from tract sales.
Book value per share reached $34.78, an 11% increase year-over-year, reflecting strong underlying asset value.
Forestar ended the year with $968 million in liquidity and nearly 100,000 lots in inventory, underpinned by a robust investment strategy.
The company continues to strengthen ties with key customers, particularly D.R. Horton, aiming for significant growth in lot sales through strategic partnerships.

View recap

Fortress Transportation and Infrastructure Investors LLC

FTAI Q3 2025

Reported: 2025-10-28

FTAI Aviation reported strong Q3 2025 results, driven by robust demand in the aerospace products sector and significant milestones in their strategic capital initiatives. The company has increased its equity capital target to $2 billion following successful fundraising efforts.

Key takeaways

Q3 adjusted EBITDA for Aerospace Products reached $180 million, reflecting a 35% margin and a 77% year-over-year increase.
Successfully closed on the final equity commitments for the $6 billion Strategic Capital Initiative (SCI), with a 19% minority interest held by FTAI.
207 CFM56 modules refurbished this quarter, a 13% increase from the previous quarter, keeping the company on track to meet its 2025 production goal of 750 modules.
Acquisition of ATOPS for $15 million bolsters FTAI's capabilities in Miami, enhancing MRE operations and supporting future production growth.
Increased focus on long-term partnerships with airlines, evidenced by new agreements such as the multiyear power program with Finnair, positioning FTAI as a leader in engine aftermarket maintenance.

View recap

Corning Incorporated

GLW Q3 2025

Reported: 2025-10-28

Corning Inc. delivered a robust third quarter with sales up 14% to $4.27 billion and EPS increasing 24% to $0.67, reflecting solid momentum from its strategic Springboard plan.

Key takeaways

Operating margin expanded 130 basis points to 19.6%, with ROIC up 160 basis points to 13.4%.
Year-to-date, Corning has achieved $4 billion in incremental annualized sales since launching its Springboard initiative.
Increased fourth quarter guidance anticipates sales of $4.35 billion, contributing an additional $300 million to the annualized sales run rate.
Success in mobile consumer electronics, highlighted by a significant contract with Apple for U.S. production, positions Corning for long-term growth.
Strong demand in optical communications driven by the expanding scale of AI data centers, bolstering growth potential in this segment.

View recap

Hillgrove Resources Limited

HGO.AX Q3 2025

Reported: 2025-10-28

Hillgrove Resources reported a strong September quarter with a record production of copper, increased operational stability, and significant reductions in all-in sustaining costs, aligning with strategic growth initiatives.

Key takeaways

Copper production increased by 8% to 2,808 tonnes, achieving annualized output of 1.5 million tonnes.
Gross all-in sustaining costs decreased by 10% compared to the previous quarter, reflecting operational efficiencies.
The Nugent ramp-up commenced ahead of schedule, with stoping activities already underway, paving the way for additional production growth.
Successful exploration at the Emily Star region shows potential for a third mining front, further enhancing resource capability.
An AUD 28 million capital placement was completed to bolster financial positioning for growth initiatives.

View recap

The Hartford Financial Services Group, Inc.

HIG Q3 2025

Reported: 2025-10-28

The Hartford Insurance Group achieved record core earnings of $1.1 billion in Q3 2025, reflecting strong premium growth and disciplined underwriting practices across its segments.

Key takeaways

Core earnings reached $3.78 per diluted share, driven by solid performance in Business Insurance with 9% written premium growth and an underlying combined ratio of 89.4%.
Personal Insurance saw a 10% growth in homeowners' premiums, coupled with a 3.6-point improvement in auto underlying combined ratios.
Employee Benefits posted an impressive core earnings margin of 8.3%, contributing to a 12-month core earnings return on equity (ROE) of 18.4%.
Strategic pricing execution across Business Insurance resulted in renewal written pricing increases averaging 7.3%, supporting sustained profitability in a competitive market.
The launch of "Prevail" enhances the product offering for retail distribution, with plans for expanded rollout to 30 states by early 2027.

View recap

Herc Holdings Inc.

HRI Q3 2025

Reported: 2025-10-28

Herc Holdings, Inc. demonstrated solid performance in Q3 2025, successfully integrating a major acquisition while adapting to a mixed demand environment, positioning itself for future growth.

Key takeaways

Completed full systems integration within 90 days, significantly faster than industry norms, enhancing operational efficiency.
Expanded sales teams underwent comprehensive training on enhanced analytics and customer engagement tools to boost customer retention and sales performance.
Optimized branch network to consolidate redundancies and increase specialty locations by 25%, thereby enhancing competitive positioning in high-margin categories.
Implemented a strategic focus on productivity, expense management, and fleet optimization, targeting improvements across underperforming locations.
Continued strong activity in mega projects while navigating limited growth in local markets due to high interest rates.

View recap

HSBC Holdings plc

HSBA.L Q3 2025

Reported: 2025-10-28

HSBC Holdings plc delivered a robust third quarter, achieving a year-to-date annualized RoTE of 17.6% and driving revenues up 3% year-over-year, bolstered by strong banking and wealth management activities.

Key takeaways

Revenues rose to $17.9 billion, driven by a $500 million increase and a remarkable 29% growth in wealth management fee income.
Customer deposits grew to $1.7 trillion, indicating healthy liquidity and operational strength.
Announced plans to privatize Hang Seng Bank, which is expected to enhance operational efficiencies and align business strategies in the Hong Kong market.
Upgraded full-year banking net interest income guidance to $43 billion, benefiting from increased deposit volumes and a recovering interest rate environment.
Exited nonstrategic activities, including HSBC Malta and Retail Banking in Sri Lanka, as part of a disciplined capital allocation strategy.

View recap

HSBC Holdings plc

HSBC Q3 2025

Reported: 2025-10-28

HSBC Holdings plc delivered a robust performance in Q3, reporting revenues of $17.9 billion and an annualized RoTE of 17.6% year-to-date, underscoring strong operational momentum and strategic execution.

Key takeaways

Total revenues increased by $500 million year-over-year, with banking NII reaching $11 billion, reflecting effective deposit growth.
Wealth management showed impressive growth with a 29% rise in fee and other income, contributing to total invested assets of $1.5 trillion.
The strategic decision to privatize Hang Seng Bank is expected to create operational efficiencies and align with HSBC’s growth objectives, while capitalizing on the positive outlook for Hong Kong.
The bank is on track for a 50% dividend payout ratio by 2025, maintaining a CET1 capital ratio of 14.5% amidst ongoing cost management efforts.
HSBC continues to exit nonstrategic markets, announcing exits in Malta and Sri Lanka, bringing the total for the year to 11.

View recap

Independent Bank Corp.

IBCP Q3 2025

Reported: 2025-10-28

Independent Bank Corporation reported robust third quarter 2025 results, with net income rising 27% year-over-year, driven by strong loan growth and consistent net interest income expansion.

Key takeaways

Net income increased to $17.5 million, or $0.84 per diluted share, up from $13.8 million, or $0.65 per diluted share, a year ago.
Year-over-year tangible common equity per share rose 10.2%, supported by efficient expense management, evidenced by a 58.86% efficiency ratio.
Total deposits reached $4.9 billion with core deposit growth of $148.2 million, reflecting solid increases in business and municipal deposits.
Commercial loan portfolio growth of 12.9% annualized year-to-date, with a diverse concentration and robust pipeline for future origination.
Credit quality remains strong, with nonperforming assets at 0.38% of total assets, reflecting isolated issues in specific commercial relationships.

View recap

Iberdrola, S.A.

IBE.MC Q3 2025

Reported: 2025-10-28

Iberdrola's reported net profit surged 17% to EUR 5,307 million in the first nine months of 2025, driven by strong EBITDA growth in the Networks segment, despite challenges in the Renewables division.

Key takeaways

Reported EBITDA rose to EUR 12,438 million, with the Networks business contributing significantly due to a 26% increase linked to a higher regulated asset base.
Total investment peaked at EUR 9 billion, a 4% increase year-over-year, with 60% allocated to Networks and intensified spending in the UK and the US.
Operating cash flow increased 10% to EUR 9,752 million, facilitating a EUR 3.2 billion reduction in consolidated net debt, now at EUR 48.5 billion, improving leverage ratios.
Interim shareholder remuneration has been raised by 8.2% to EUR 0.25 per share, reflecting a solid commitment to returning value to shareholders.
Progress in the renewable sector includes the installation of over 2,000 megawatts in the last year, with significant advancements in offshore wind projects.

View recap

Incyte Corporation

INCY Q3 2025

Reported: 2025-10-28

Incyte reported a strong Q3 2025, with total revenues of $1.37 billion and product sales of $1.15 billion, reflecting year-over-year growth of 20% and 19%, respectively, driven by robust demand for Jakafi and Opzelura.

Key takeaways

Jakafi sales reached $791 million, a 7% increase, with broad-based growth across all indications and market share leadership maintained in MF.
Opzelura achieved $188 million in sales, up 35% year-over-year, bolstered by strong prescription demand and improved formulary access.
Niktimvo exceeded launch expectations with $46 million in Q3 sales, capturing 13% of the third-line GVHD opportunity shortly after launch.
Incyte raised its full-year guidance for Jakafi to $3.05 billion to $3.075 billion based on current momentum.
Upcoming product launches in 2026 are positioned to enhance growth prospects, including ruxolitinib XR and additional indications for Opzelura.

View recap

IQVIA Holdings Inc.

IQV Q3 2025

Reported: 2025-10-28

IQVIA reported solid third-quarter 2025 results, with revenues and profits at the high end of guidance, driven by robust operational performance and impressive free cash flow.

Key takeaways

Revenue growth of 5.2% year-over-year, with adjusted diluted EPS rising 5.6%.
Record backlog of $32.4 billion, up 4.1% compared to the prior year, reflecting strong demand trends.
Net bookings reached $2.6 billion, translating to a favorable net book-to-bill ratio of 1.15x, driven by improved customer demand.
Continued strength in the TAS segment with successful drug launches contributing to overall results.
Strong free cash flow this quarter marks the highest ever, highlighting effective working capital management.

View recap

Invesco Ltd.

IVZ Q3 2025

Reported: 2025-10-28

Invesco delivered robust growth in Q3, driven by strategic initiatives aimed at enhancing profitability, simplifying operations, and leveraging market opportunities.

Key takeaways

Repurchased approximately 25% of term loans linked to a $1 billion preferred stock buyback, boosting earnings accretion.
Launched the Invesco Dynamic Credit Opportunity Fund in collaboration with Barings, meeting increased demand for income-oriented investment solutions.
Continued transition to a hybrid investment platform, with the second wave of equity AUM shifted to the Alpha platform, enhancing operational efficiency.
Generated $100 million in net cash from the sale of the Intelliflo subsidiary, set to close in Q4, with potential for additional earn-outs.
Advanced efforts to modernize the QQQ ETF, with strong shareholder approval momentum for proposed structural changes.

View recap

Keurig Dr Pepper Inc.

KDP Q3 2025

Reported: 2025-10-28

Keurig Dr Pepper (KDP) reports solid Q3 results, driven by its strategic focus on value creation through the upcoming JDE Peet's acquisition and the planned business separation.

Key takeaways

KDP achieved a 6% revenue CAGR and an 11% EPS CAGR since formation, positioning it among top-tier CPG peers.
The company emphasizes confidence in its strategic acquisition of JDE Peet's as a catalyst for future growth in the global coffee market.
Management highlighted a recovery in the global coffee category post-COVID-19, with expectations for meaningful long-term volume growth.
KDP’s flexible execution strategy aims to maximize value through the business integration and separation process.
Leadership underscored the strength of the Keurig brand as it aligns with the broader growth potential of a global coffee powerhouse.

View recap

Kiniksa Pharmaceuticals, Ltd.

KNSA Q3 2025

Reported: 2025-10-28

Kiniksa Pharmaceuticals reported strong third-quarter results, with ARCALYST revenue reaching $180.9 million, reflecting significant growth and a revised full-year sales guidance increase.

Key takeaways

ARCALYST revenue grew by approximately $69 million year-over-year and $24 million sequentially.
Full-year net sales guidance raised to $670 million - $675 million, up from previous guidance of $625 million - $640 million.
KPL-387 received FDA Orphan Drug Designation for recurrent pericarditis, enhancing future growth potential.
New patient enrollments surged, with a total prescriber count exceeding 3,825, indicating strong market penetration and adoption.
The average duration of ARCALYST therapy increased to approximately 32 months, reflecting patient satisfaction and treatment effectiveness.

View recap

Koninklijke KPN N.V.

KPN.AS Q3 2025

Reported: 2025-10-28

KPN's Q3 performance demonstrated solid growth with service revenues rising 1.7% and adjusted EBITDA increasing by 4.4%, reflecting robust commercial momentum and strategic execution across all segments.

Key takeaways

Service revenues grew 1.7% year-on-year, supported by strong performance in consumer and business segments.
Adjusted EBITDA increased by 4.4%, benefitting from higher service revenues and operational efficiency.
Free cash flow surged 12% year-to-date, indicating improved working capital management and lower interest payments.
Fiber footprint expanded significantly, with 74,000 more homes passed, aligning with the goal to cover 80% of Dutch households.
Customer satisfaction improved, as reflected in rising Net Promoter Scores across consumer and business segments.

View recap

Leggett & Platt, Incorporated

LEG Q3 2025

Reported: 2025-10-28

Leggett & Platt delivered solid third-quarter results despite ongoing challenges in residential markets, reaffirming full-year sales and adjusted EPS guidance while successfully executing its restructuring plan.

Key takeaways

Third-quarter sales were over $1 billion, down 6% year-over-year, primarily due to weak residential demand and divestiture impacts.
Bedding product sales fell 10% year-over-year, but showed a sequential improvement of 3%, indicating some stabilization in demand.
Significant progress on the restructuring plan has improved cash flow and decreased net debt, with completion of the flooring consolidation projected by year-end.
The divestiture of the Aerospace business has optimized the portfolio and strengthened the balance sheet.
Ongoing global supply chain risks, particularly in the automotive sector, are being monitored, but no material impacts have been felt thus far.

View recap

MSCI Inc.

MSCI Q3 2025

Reported: 2025-10-28

MSCI reported robust Q3 2025 results, delivering a 9% organic revenue growth and a 15% increase in adjusted earnings per share, supported by strong demand across its Index and Analytics segments.

Key takeaways

Achieved record total assets under management (AUM) of $6.4 trillion linked to MSCI indices, reinforcing the firm's leadership position in the index market.
Strong performance in subscription sales with a 27% increase in Index and 16% in Analytics, showcasing demand for risk tools by hedge funds.
Continued commitment to shareholder value with $1.25 billion in share repurchases during Q3 and an additional $3 billion authorized for future buybacks.
Introduction of innovative products, including a private credit factor model and MSCI PACS taxonomy, leveraging AI to enhance transparency and standardization in private assets.
Significant growth momentum in the hedge fund and wealth management segments, underscoring the value of MSCI's solutions amid market volatility.

View recap

Materialise NV

MTLS Q3 2025

Reported: 2025-10-28

Materialise reported third-quarter earnings with robust growth in its medical unit, buoyed by advancements in cardiac technology, despite overall revenue remaining under pressure.

Key takeaways

Medical unit achieved double-digit growth, driven by innovative product launches and clinical evidence.
Acquisition of FEops enhances capabilities in AI-driven heart intervention simulations, improving procedural efficiency.
New versions of existing software, including Mimics Enlight CMF, integrate AI for faster and more accurate surgical planning.
Continued progress in establishing CO-AM as a comprehensive ecosystem for additive manufacturing operations, supporting scalability and efficiency.
Anticipation builds for upcoming presentations at Formnext, highlighting advancements and product capabilities.

View recap

NBT Bancorp Inc.

NBTB Q3 2025

Reported: 2025-10-28

NBT Bancorp delivered strong Q3 2025 results, demonstrating solid operating leverage and significant improvements in net interest margin, aided by the successful integration of Evans Bancorp.

Key takeaways

Net income rose to $54.5 million, equating to $1.03 per diluted share, with operating earnings of $1.05, up 19% from Q2.
Net interest margin expanded for the sixth consecutive quarter, reflecting ongoing asset repricing and prudent funding cost management.
Deposits increased by $2.1 billion year-to-date, driven by strong growth in checking and money market accounts, underpinned by the acquisition of Evans Bancorp.
The company announced an 8.8% dividend increase, marking 13 consecutive years of dividend growth, reflecting robust capital strength and earnings consistency.
Continued strategic expansion is planned with new branch openings in key markets, including Greater Rochester and Portland, Maine, to enhance regional presence.

View recap

NextEra Energy, Inc.

NEE Q3 2025

Reported: 2025-10-28

NextEra Energy reported a robust Q3 2025 with a 9.7% year-over-year increase in adjusted earnings per share, confirming strong operational performance across its segments.

Key takeaways

Adjusted EPS increased by 9.7% in Q3 2025 and 9.3% year-to-date, demonstrating consistent financial growth.
Florida Power & Light (FPL) plans to invest approximately $40 billion over the next four years to expand energy infrastructure, focusing on solar, battery storage, and gas generation.
FPL's proposed 4-year rate agreement aims for stable customer bills with only a 2% annual increase, maintaining prices significantly below national averages.
NextEra Energy's renewables strategy is strengthened by recent federal tax credit outcomes, facilitating enhanced development of solar and storage capacity through 2030.

View recap

NOS, S.G.P.S., S.A.

NOS.LS Q3 2025

Reported: 2025-10-28

NOS reported a mixed Q3 2025 performance with consolidated revenues declining 1.2% to EUR 457 million, attributed to a challenging audiovisual market, while EBITDA grew 2.7% thanks to strong operational efficiency and cost management.

Key takeaways

EBITDA increased 2.7%, driven by improved operational efficiencies and lower operating expenses, achieving a notable 4.6% OpEx reduction.
Net income surged 25% to EUR 65 million, reflecting robust operational performance and effective cost management strategies.
RGUs reached 10.9 million, marking a 2% increase with 131,000 net additions, the highest since 2023, primarily from fixed and mobile segments.
CapEx reduced by 2% to EUR 91.5 million, contributing to a 9.6% rise in EBITDA AL minus CapEx, showcasing disciplined investment amid revenue pressures.
Financial leverage improved to 1.6x with debt decreasing to EUR 1,093 million, highlighting a solid balance sheet and a lower average cost of debt now below 2.8%.

View recap

NOV Inc.

NOV Q3 2025

Reported: 2025-10-28

NOV demonstrated resilience in Q3 2025, reporting stable revenues of $2.18 billion and strong free cash flow, despite facing a challenging macro environment and declining oilfield activity.

Key takeaways

Revenue of $2.18 billion was down just 0.4% year-over-year, with EBITDA increasing to $258 million, representing 11.9% of revenue.
Free cash flow increased to $245 million, showcasing effective cost management and project execution.
Energy Equipment's strong demand led to record revenues in subsea flexible pipe and gas-focused process systems, with significant year-over-year margin expansion across key segments.
Drilling activity slightly outperformed global rig count declines, supported by enhanced downhole technologies and increasing demand for proprietary products.
Future prospects are optimistic, driven by the globalization of unconventional shale and a resurgence in deepwater development, which is expected to attract significant investment over the next decade.

View recap

Novartis AG

NOVN.SW Q3 2025

Reported: 2025-10-28

Novartis posted strong Q3 2025 results, bolstered by 7% sales growth and key pipeline advancements, sustaining momentum across multiple therapeutic areas.

Key takeaways

Sales and core operating income each increased by 7%, with core operating margin at 39.3%.
Kisqali led the charge with a 68% sales increase, driven by strong early breast cancer uptake, marking significant market leadership.
Noteworthy pipeline achievements include FDA approval of Rhapsido and positive Phase III data for Ianalumab, Pluvicto, and Cosentyx.
Kesimpta saw robust 44% growth in Q3, indicating strong demand, especially in first-line therapy, across global markets.
Pluvicto accelerated by 45% in constant currencies, strengthened by a new approval for pre-taxane castrate-resistant prostate cancer.

View recap

Nucor Corporation

NUE Q3 2025

Reported: 2025-10-28

Nucor Company delivered robust third-quarter results, achieving EBITDA of approximately $1.3 billion and EPS of $2.63, surpassing guidance amid strong steel mill shipments and strategic operational enhancements.

Key takeaways

EBITDA increased to $1.3 billion, driven by higher steel mill shipments and corporate adjustments.
Reinvested $807 million into growth projects while returning nearly $1 billion to shareholders year-to-date, reinforcing capital management strategy.
Achieved A3 credit rating upgrade from Moody's, positioning Nucor as the only major North American steel producer with top-tier ratings from all three agencies.
Established new production capabilities with successful ramp-ups in Arizona and North Carolina to capture growth in the construction and data center markets.
Maintained focus on optimizing existing asset base and strategic investments to enhance competitive advantages in steel solutions.

View recap

Novartis AG

NVS Q3 2025

Reported: 2025-10-28

Novartis reported robust Q3 2025 results with a 7% increase in sales and core operating income, driven by strong performance from key growth drivers and critical pipeline advancements.

Key takeaways

Core operating income margin held steady at 39.3%, reflecting efficient cost management amid competitive pressures.
Kisqali saw exceptional growth of 68%, leading in both early and metastatic breast cancer markets, with U.S. sales up 91%.
Kesimpta experienced 44% growth, bolstered by strong first-line patient access and significant market share in major territories.
Pluvicto achieved 45% growth, driven by recent approvals and increasing community adoption, supporting a path to peak sales potential.
Successful FDA approvals and positive Phase III data reinforce Novartis’ growth trajectory and pipeline strength.

View recap

NXP Semiconductors N.V.

NXPI Q3 2025

Reported: 2025-10-28

NXP's Q3 2025 results exceeded revenue guidance, driven by solid sequential growth across all regions and end markets, despite a slight year-on-year decline.

Key takeaways

Q3 revenue reached $3.17 billion, exceeding guidance by $23 million, marking an 8% sequential growth but down 2% year-on-year.
Non-GAAP operating margin stood at 34%, slightly above guidance, influenced by stable operating expenses.
Q4 revenue is projected at $3.3 billion, reflecting continued growth dynamics, especially in automotive and industrial segments.
Recent acquisitions of Kinara and Aviva Links have closed, enhancing NXP's market positioning for future growth.
Customer backlog and improved order conditions indicate a strengthening operational outlook, despite prevailing macroeconomic uncertainties.

View recap

Olin Corporation

OLN Q3 2025

Reported: 2025-10-28

Olin Corporation reported strong third-quarter results, highlighting robust performance in its Chlor Alkali Products and Vinyls segments, while managing challenges in its Epoxy and Winchester businesses.

Key takeaways

Adjusted EBITDA rose to $190 million, excluding a $32 million benefit from clean hydrogen production tax credits, marking an 8% sequential improvement.
Chlor Alkali Products and Vinyls benefitted from stable caustic soda demand and operational improvements, despite anticipated seasonally lower fourth-quarter demand.
Epoxy segment faced ongoing demand weakness, particularly from subsidized Asian imports, with planned maintenance expected to impact earnings by $14 million in Q4.
Winchester faced significant commercial challenges with a projected 5-10% sales decline due to high retail inventories, while military demand remains strong, supporting ongoing defense contracts.
The dissolution of the Blue Water Alliance joint venture allows for strategic realignment in the EDC market, focusing on long-term relationships rather than short-term exposure.

View recap

Piedmont Office Realty Trust, Inc.

PDM Q3 2025

Reported: 2025-10-28

Piedmont's third quarter 2025 results reflect a significant turnaround in U.S. office demand, achieving record leasing levels and exceeding consensus FFO estimates. The company stands poised for sustainable earnings growth driven by strong market dynamics.

Key takeaways

Positive absorption in U.S. office space reached 12 million square feet in Q3, marking the first increase since late 2021.
Despite a challenging hiring landscape, leasing of 724,000 square feet for new tenants in Q3 was the highest in over a decade, contributing to a year-to-date total of approximately 1.8 million square feet.
Piedmont's in-service lease percentage increased to 89.2%, positioning the company to achieve its year-end leasing goal.
Over $40 million in annualized uncommenced leases have been secured, with expected commencement by the end of 2026, indicating strong future earnings potential.
Rental rates across the portfolio have increased significantly, bolstered by competition for premium spaces and limited supply, with some properties now commanding rates up to $48 per square foot.

View recap

Polaris Inc.

PII Q3 2025

Reported: 2025-10-28

Polaris reported robust third-quarter performance with sales of $1.8 billion, driven by strong Off-Road and Marine segments, while strategically divesting a majority stake in Indian Motorcycle to enhance focus on core business.

Key takeaways

Sales increased 7% year-over-year, bolstered by a richer product mix and a 9% rise in North American retail.
Dealer inventory significantly improved, decreasing 21% year-over-year and contributing to enhanced dealer financial health.
Adjusted EPS reached $0.41, reflecting operational efficiencies despite pressures from tariffs and incentive compensation normalization.
The company is reintroducing full year 2025 guidance amid close monitoring of consumer health indicators and expects sequential sales growth in Q4.
Polaris gained approximately 3 points of market share in Off-Road vehicles, successfully leveraging its innovative product offerings.

View recap

PayPal Holdings, Inc.

PYPL Q3 2025

Reported: 2025-10-28

PayPal Holdings, Inc. reported strong third-quarter results, with notable improvements in revenue growth and transaction margins, underscoring its shift towards profitable expansion.

Key takeaways

Non-GAAP EPS increased by 12%, driven by transaction margin dollar growth across multiple business segments.
Monthly active accounts grew by 2%, and transactions per active account rose by 5%, indicating deeper customer engagement.
The company is on track for 15% non-GAAP EPS growth in 2025, highlighting its successful focus on profitable growth strategies.
PayPal is initiating a dividend and continuing its share buyback program, reflecting strong cash flow and commitment to returning capital to shareholders.
The branded experiences segment saw 8% TPV growth on a currency-neutral basis, affirming PayPal's evolution into a broader commerce company.

View recap

Regeneron Pharmaceuticals, Inc.

REGN Q3 2025

Reported: 2025-10-28

Regeneron Pharmaceuticals reported solid third quarter results for 2025, with robust sales growth driven by Dupixent and Libtayo, complemented by EYLEA HD achieving record revenue despite ongoing affordability challenges.

Key takeaways

Dupixent generated $4.9 billion in global net sales, a 26% increase year-over-year, with dominance in multiple indications and growing patient base.
Libtayo sales reached $365 million, up 24% year-over-year, bolstered by a recent FDA approval for use in high-risk adjuvant cutaneous squamous cell carcinoma.
EYLEA HD sales hit an all-time high of $431 million in the U.S., driven by increased physician demand, though impacted by pricing pressures and market affordability issues.
Ongoing regulatory challenges with prefilled syringe approvals for EYLEA HD could affect future growth potential; alternate filling plans set for submission by January 2026.
Significant R&D progress announced with positive Phase III results across diverse therapeutic areas, enhancing pipeline momentum ahead of upcoming pivotal studies.

View recap

Resolute Mining Limited

RSG.AX Q3 2025

Reported: 2025-10-28

Resolute Mining delivered solid production and increased cash flow in Q3 2023, despite operational challenges at Syama, leading to a revised production guidance primarily due to higher royalty costs.

Key takeaways

Gold poured totaled 59,807 ounces in Q3, contributing to a year-to-date total of 211,000 ounces, with an average gold price of $3,400 per ounce.
All-in sustaining costs (AISC) rose to $2,205 per ounce due to increased royalty expenses amid a higher gold price environment.
Revised production guidance for the year, narrowing to 275,000 to 285,000 ounces, reflecting operational challenges particularly at Syama.
Significant resource growth at the Doropo project, now estimated at 4.4 million ounces, bolstering long-term production prospects.
Cash generation remained robust, with approximately $26 million for the quarter, ending with a net cash position of $136 million.

View recap

Seven Hills Realty Trust Common Stock

SEVN Q3 2025

Reported: 2025-10-28

Seven Hills Realty Trust reported robust third-quarter results, achieving distributable earnings of $4.2 million, driven by a solid loan portfolio and strategic capital deployment. The company declared a quarterly dividend of $0.28 per share, reflecting an attractive annualized yield of 11%.

Key takeaways

Distributable earnings reached $4.2 million, or $0.29 per share, at the top end of guidance.
Recent transactions include a $34.5 million mortgage loan in Manhattan and a forthcoming $37.3 million loan for a student housing property.
The portfolio consists of $642 million in floating rate first mortgage commitments with an 8.2% weighted average yield; all loans are current on debt service.
Increased borrower engagement and expected further rate cuts suggest a strengthening lending environment moving into 2026.
The company's pipeline is robust, evaluating over $1 billion in loan opportunities, with a shift toward acquisition financing indicating improved market confidence.

View recap

The Sherwin-Williams Company

SHW Q3 2025

Reported: 2025-10-28

Sherwin-Williams reported solid Q3 2025 results, with sales growth outpacing softer demand conditions, as strategic investments continue to yield returns amid a challenging economic backdrop.

Key takeaways

Consolidated sales increased at the high end of guidance, driven by strong performance from the Paint Stores Group and Consumer Brands Group, with adjusted EBITDA margin expanding 60 basis points to 21.4%.
SG&A expenses rose moderately in the low single-digit range, consistent with expectations, as the company maintained control over general and administrative costs.
The company returned $864 million to shareholders through dividends and share repurchases, reinforcing their commitment to returning value.
The acquisition of Suvinil enhances growth prospects in the Consumer Brands Group, particularly in Latin America, amid ongoing channel optimization efforts.
Segment profit growth in the Paint Stores Group reflects effective leveraging of SG&A, achieving over 30% incremental margin on low single-digit volume growth.

View recap

SoFi Technologies, Inc.

SOFI Q3 2025

Reported: 2025-10-28

SoFi Technologies reported a remarkable Q3 2025, highlighting a record membership growth and substantial revenue increase, driven by strategic investments in product innovation and brand expansion.

Key takeaways

Achieved a record 905,000 new members, propelling total membership to 12.6 million, a 35% year-over-year increase.
Adjusted net revenue reached $950 million, a 38% year-over-year growth, with Financial Services and Technology Platform segments generating $534 million—a 57% increase.
Record total originations of $9.9 billion in Q3, with strong performance from both lending and loan platform businesses.
Adjusted EBITDA rose to a record $277 million, up nearly 50% year-over-year, reflecting a strong EBITDA margin of 29%.
Launched SoFi Pay, a blockchain-enabled payment product, tapping into the technology super cycles in AI and blockchain.

View recap

Grupo Traxion, S.A.B. de C.V.

TRAXIONA.MX Q3 2025

Reported: 2025-10-28

Grupo Traxion successfully integrated Solistica, driving a notable increase in revenue while maintaining leverage and interest expenses, despite challenges in cargo and logistics operations.

Key takeaways

Successful completion of Solistica integration is expected to generate MXN 8 billion in additional revenue.
Revenue uplift against a backdrop of reduced organic CapEx, allowing focus on merger efficiencies.
Net income increased by over 17%, outpacing both revenue and EBITDA growth.
Net debt to EBITDA ratio remained stable at 2.35x, underscoring financial health post-acquisition.
Anticipated revenue growth in the mid-teens for year-end, despite sector challenges.

View recap

two

TWO Q3 2025

Reported: 2025-10-28

TWO reported a challenging third quarter with a negative economic return of 6.3% mainly due to a $375 million litigation settlement expense, but underlying operational metrics remain robust and continue to leverage their strategic subservicing initiatives.

Key takeaways

Completed a $375 million settlement with former external management, funded through portfolio adjustments.
Adjusted RMBS portfolio size and successfully increased third-party subservicing UPB to approximately $40 billion.
Achieved record direct-to-consumer locks and originated $49 million in loans, indicating strong growth potential despite a lower capital base.
Plans to redeem $262 million in convertible notes by January 2026 to align structural leverage with historical norms.
Confident about future growth opportunities and view current stock valuation as significantly undervalued compared to peers.

View recap

UnitedHealth Group Incorporated

UNH Q3 2025

Reported: 2025-10-28

UnitedHealth Group's third quarter results confirm strong operational execution, with a focus on enhancing margins in 2026 despite challenges in medical cost trends and ongoing industry-wide Medicare funding pressures.

Key takeaways

Medical cost trends remain consistent with previous guidance, forecasting a 7.5% trend for Medicare Advantage in 2025.
Strategic repricing in UnitedHealthcare and targeted adjustments in benefits are positioned to drive margin growth in 2026.
Anticipated membership contraction of approximately 1 million in Medicare Advantage is expected as part of a cautious approach to offset elevated medical trends.
Improvements in Medicare STARS scores and disciplined execution signal a commitment to operational efficacy and long-term performance recovery.
Ongoing investments in developing Optum's capabilities will lead to sustained growth, with a focus on refining healthcare delivery and aligning clinical services.

View recap

United Parcel Service, Inc.

UPS Q3 2025

Reported: 2025-10-28

UPS reported third-quarter 2025 results featuring $21.4 billion in revenue and $2.1 billion in operating profit, reflecting a strategic focus on revenue quality amidst declining daily volumes, particularly in the U.S.

Key takeaways

U.S. average daily volume (ADV) declined by 12.3% year-over-year, primarily due to a planned reduction in Amazon and lower-yielding e-commerce volumes.
Revenue per piece increased by 9.8%, contributing to a stable operating margin of 10% despite declines in ADV.
Year-to-date free cash flow improved to $2.7 billion, alleviating prior cash flow pressures.
Significant growth in health care logistics, with revenue driven by strategic acquisitions aimed at enhancing service capabilities.
Digital Access Program (DAP) revenue rose 20% year-over-year, reaching over $2.8 billion in just nine months, highlighting continued strength in the SMB market.

View recap

Wayfair Inc.

W Q3 2025

Reported: 2025-10-28

Wayfair's third quarter of 2025 demonstrated strong performance with 9% revenue growth and a remarkable 70% increase in adjusted EBITDA year-over-year, marking a significant rebound despite ongoing challenges in the housing market.

Key takeaways

Revenue grew 9% year-over-year (excluding Germany), with orders increasing over 5%.
Adjusted EBITDA surged by 70%, achieving a record margin of 6.7% outside the pandemic period.
Active customer count rose sequentially for the first time since 2023, indicating positive momentum.
Successful implementation of technology initiatives like Wayfair Rewards and enhanced AI capabilities contributing to structural growth.
Resilience shown in adapting to market conditions while maintaining competitive pricing strategies.

View recap

GeneDx Holdings Corp. Class A Common Stock

WGS Q3 2025

Reported: 2025-10-28

GeneDx's Q3 2025 results showcase robust financial performance with record growth, prompting an upward revision of revenue guidance to $425-$428 million for the year, supported by increased commercialization efforts and key executive hires.

Key takeaways

Revenue growth remains strong with ongoing profitability, reflecting effective execution of the company’s strategic initiatives.
FDA granted breakthrough device designation for ExomeDx and GenomeDx, solidifying GeneDx's leadership in rare disease diagnostics.
Plans to nearly double the sales force to enhance penetration in pediatrician markets, with a focus on driving adoption of genomic testing.
Continued expansion into under-penetrated NICU markets, with a goal to significantly scale genetic testing in critical care settings.
Active involvement in innovative newborn screening initiatives underlines GeneDx’s commitment to proactive, equitable healthcare solutions.

View recap

Xylem Inc.

XYL Q3 2025

Reported: 2025-10-28

Xylem delivered strong third-quarter results, achieving a 7% revenue growth driven by strong demand across segments and record EBITDA margins exceeding 23%. The company raised its full-year guidance for revenue, margin, and EPS, reflecting continued operational momentum.

Key takeaways

Revenue grew 7% year-over-year, with particularly strong performances in Measurement and Control Solutions and Water Solutions and Services.
EBITDA margin expanded by 200 basis points to a record 23%, reflecting successful simplification efforts and pricing strategies.
While orders decreased slightly by 2%, backlog remains robust at approximately $5 billion, supporting future revenue visibility.
The divestiture of the international metering business is expected to enhance operational focus and improve margins significantly.
With a net debt to adjusted EBITDA ratio of 0.4x, Xylem maintains a strong balance sheet, enabling continued investment in growth initiatives.

View recap

Zebra Technologies Corporation

ZBRA Q3 2025

Reported: 2025-10-28

Zebra Technologies reported strong third-quarter results, with sales reaching $1.3 billion, representing a 5% year-over-year increase, alongside improved operational efficiencies driving double-digit earnings growth.

Key takeaways

Adjusted EBITDA margin rose to 21.6%, reflecting a 20 basis point improvement year-over-year.
Non-GAAP diluted EPS of $3.88 increased 11% YoY, exceeding market expectations.
Sales growth was driven by strong demand in North America and Asia Pacific, particularly in mobile computing and RFID segments.
Zebra plans $500 million in share repurchases over the next 12 months, reflecting confidence in long-term value creation.
The company anticipates Q4 sales growth of 8% to 11%, bolstered by recent acquisitions and favorable currency effects.

View recap

Earnings Recaps

Alkermes plc

Amkor Technology, Inc.

American Tower Corporation (REIT)

A. O. Smith Corporation

Arcutis Biotherapeutics, Inc.

Allegheny Technologies Incorporated

Bed Bath & Beyond Inc.

Brown & Brown, Inc.

Avis Budget Group, Inc.

Carrier Global Corporation

Cadence Design Systems, Inc.

Confluent Inc. Class A Common Stock

Georgia Capital PLC

Check Point Software Technologies Ltd.

Crane Co.

D.R. Horton, Inc.

Forestar Group Inc.

Fortress Transportation and Infrastructure Investors LLC

Corning Incorporated

Hillgrove Resources Limited

The Hartford Financial Services Group, Inc.

Herc Holdings Inc.

HSBC Holdings plc

HSBC Holdings plc

Independent Bank Corp.

Iberdrola, S.A.

Incyte Corporation

IQVIA Holdings Inc.

Invesco Ltd.

Keurig Dr Pepper Inc.

Kiniksa Pharmaceuticals, Ltd.

Koninklijke KPN N.V.

Leggett & Platt, Incorporated

MSCI Inc.

Materialise NV

NBT Bancorp Inc.

NextEra Energy, Inc.

NOS, S.G.P.S., S.A.

NOV Inc.

Novartis AG

Nucor Corporation

Novartis AG

NXP Semiconductors N.V.

Olin Corporation

Piedmont Office Realty Trust, Inc.

Polaris Inc.

PayPal Holdings, Inc.

Regeneron Pharmaceuticals, Inc.

Resolute Mining Limited

Seven Hills Realty Trust Common Stock

The Sherwin-Williams Company

SoFi Technologies, Inc.

Grupo Traxion, S.A.B. de C.V.

two

UnitedHealth Group Incorporated

United Parcel Service, Inc.

Wayfair Inc.

GeneDx Holdings Corp. Class A Common Stock

Xylem Inc.

Zebra Technologies Corporation

Community

Trending This Week

Notifications